Drug Analysis: Imfinzi

  • ID: 4462230
  • Drug Pipelines
  • 41 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

AstraZeneca’s Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell-surface molecules and the CTLA-4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. The pathways have a similar effect on T-cell immune response but are distinct from each other (Keir et al., 2008).
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Imfinzi: Head and neck cancer
Imfinzi: Bladder cancer
durvalumab: Non-small cell lung cancer (NSCLC)

List of Figures
Figure 1: Imfinzi for head and neck cancer - SWOT analysis
Figure 2: Drug assessment summary of Imfinzi for SCCHN
Figure 3: Drug assessment summary of Imfinzi for SCCHN
Figure 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Imfinzi for urothelial bladder cancer - SWOT analysis
Figure 6: Drug assessment summary for Imfinzi in urothelial bladder cancer
Figure 7: Drug assessment summary for Imfinzi in urothelial bladder cancer
Figure 8: Durvalumab for non-small cell lung cancer - SWOT analysis
Figure 9: Drug assessment summary for durvalumab in non-small cell lung cancer
Figure 10: Drug assessment summary for durvalumab in non-small cell lung cancer

List of Tables
Table 1: Imfinzi drug profile
Table 2: Imfinzi Phase III trials in head and neck cancer
Table 3: Imfinzi early-phase data in head and neck cancer
Table 4: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 6: Imfinzi drug profile
Table 7: Imfinzi pivotal trial data in urothelial bladder cancer
Table 8: Imfinzi ongoing late-phase trials in urothelial bladder cancer
Table 9: Durvalumab drug profile
Table 10: Durvalumab Phase III trials in non-small cell lung cancer
Table 11: Durvalumab early-phase data in non-small cell lung cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll